FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo

Blood

Volumn 117, Issue 12, 2011, Pages 3286-3293

  Sato, Takashi ^a   Yang, Xiaochuan ^a   Knapper, Steven ^b   White, Paul ^b   Smith, B Douglas ^a   Galkin, Steven ^a   Small, Donald ^a   Burnett, Alan ^b   Levis, Mark ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AC 220; ANTINEOPLASTIC AGENT; FLT3 LIGAND; KW 2449; LESTAURTINIB; MIDOSTAURIN; SORAFENIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; HUMAN; HUMAN CELL; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 79953073247     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-266742     Document Type: Article

References (38)

1. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood. 2002;100(5): 1532-1542. (Pubitemid 34925124)
2. Levis M, Small D. FLT3: ITDoes matter in leukemia. Leukemia. 2003;17(9):1738-1752. (Pubitemid 37185249)
3. Levis M, Small D. FLT3 tyrosine kinase inhibitors. Int J Hematol. 2005;82(2):100-107. (Pubitemid 41233167)
4. Pratz K, Levis M. Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens. Leuk Lymphoma. 2008;49(5):852-863. (Pubitemid 351942737)
5. Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113(24): 6215-6224.
6. Levis M, Smith BD, Beran M, et al. A randomized, open-label study of lestaurtinib (CEP-701), an oral FLT3 inhibitor, administered in sequence with chemotherapy in patients with relapsed AML harboring FLT3 activating mutations: clinical response correlates with successful FLT3 inhibition [abstract]. Blood. 2005;106:Abstract 121a.
7. Kell WJ, Burnett AK, Chopra R, et al. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood. 2003; 102(13):4277-4283. (Pubitemid 37494084)
8. Cortes J, Foran J, Devetten M, et al. Human pharmacokinetics of AC220, a potent and selective class III receptor tyrosine kinase inhibitor. Blood. 2007;110(11):477a.
9. Pratz K, Cho E, Karp JE, et al. Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol. 2009;27(suppl 15):371s.
10. Smith BD, Levis M, Beran M, et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004; 103(10):3669-3676. (Pubitemid 38596280)
11. Levis M, Allebach J, Tse KF, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002; 99(11):3885-3891. (Pubitemid 35332023)
12. Weisberg E, Boulton C, Kelly LM, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002;1(5):433-443. (Pubitemid 41039124)
13. Zarrinkar PP, Gunawardane RN, Cramer MD, et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood. 2009;114(14):2984-2992.
14. Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 2007;21(3):439-445.
15. Pratz KW, Cortes J, Roboz GJ, et al. A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response. Blood. 2009;113(17):3938-3946.
16. Levis M, Brown P, Smith BD, et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. Blood. 2006;108(10): 3477-3483.
17. Knapper S, Burnett A, Hills RK, Small D, Levis M. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may influence relapse risk [abstract]. Blood. 2009;114:326a.
18. Knapper S, Burnett AK, Littlewood T, et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 2006;108(10): 3262-3270.
19. Brown P, Meshinchi S, Levis M, et al. Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood. 2004;104(6):1841-1849. (Pubitemid 39202295)
20. Weisel KC, Yildirim S, Schweikle E, Kanz L, Mohle R. Effect of FLT3 inhibition on normal hematopoietic progenitor cells. Ann N Y Acad Sci. 2007;1106:190-196. (Pubitemid 47443056)
21. Lyman SD, Seaberg M, Hanna R, et al. Plasma/serum levels of flt3 ligand are low in normal individuals and highly elevated in patients with Fanconi anemia and acquired aplastic anemia. Blood. 1995;86(11):4091-4096.
22. Wodnar-Filipowicz A, Lyman SD, Gratwohl A, Tichelli A, Speck B, Nissen C. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. Blood. 1996;88(12):4493- 4499. (Pubitemid 26419132)
23. Zwierzina H, Anderson JE, Rollinger-Holzinger I, Torok-Storb B, Nuessler V, Lyman SD. Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes. Leukemia. 1999;13(4):553-557. (Pubitemid 29195283)
24. Bojko P, Pawloski D, Stellberg W, Schroder JK, Seeber S. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy. Ann Hematol. 2002;81(9):522-528. (Pubitemid 36075505)
25. Bertho JM, Demarquay C, Frick J, et al. Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia. Int J Radiat Biol. 2001;77(6):703-712. (Pubitemid 32531887)
26. Haidar JH, Bazarbachi A, Mahfouz R, Haidar HA, Jaafar H, Daher R. Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell mobilization. J Hematother Stem Cell Res. 2002; 11(3):533-538. (Pubitemid 34615038)
27. Molyneux G, Gibson FM, Whayman M, Turton JA. Serum FLT-3 ligand in a busulphan-induced model of chronic bone marrow hypoplasia in the female CD-1 mouse. Int J Exp Pathol. 2008;89(2): 159-170. (Pubitemid 351365193)
28. Zhou J, Bi C, Janakakumara JV, et al. Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML. Blood. 2009;113(17):4052-4062.
29. Kelly LM, Yu JC, Boulton CL, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 2002;1(5):421-432. (Pubitemid 41039123)
30. Turner AM, Lin NL, Issarachai S, Lyman SD, Broudy VC. FLT3 receptor expression on the surface of normal and malignant human hematopoietic cells. Blood. 1996;88(9):3383-3390. (Pubitemid 26365572)
31. Pratz KW, Sato T, Murphy KM, Stine A, Rajkhowa T, Levis M. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood. 2010;115(7):1425-1432.
32. Shiotsu Y, Kiyoi H, Ishikawa Y, et al. KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Blood. 2009;114(8):1607-1617.
33. Stone RM, DeAngelo DJ, Klimek V, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood. 2005;105(1):54-60.
34. Qiu C, Tarrant MK, Boronina T, et al. In vitro enzymatic characterization of near full length EGFR in activated and inhibited states. Biochemistry. 2009; 48(28):6624-6632.
35. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358-364. (Pubitemid 43936934)
36. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010; 28(11):1856-1862.
37. Stone RM, Fischer T, Paquette R, et al. Phase IB study of PKC412, an oral FLT3 kinase inhibitor, in sequential and simultaneous combinations with daunorubicin and cytarabine (DA) induction and high-dose cytarabine consolidation in newly diagnosed patients with AML [abstract]. Blood. 2005; 106:121a.
38. Zheng R, Piloto O, Small D. FLT3 ligand is required for full activation of FLT3 mutants [abstract]. Blood. 2006;108(11):186a.